Literature DB >> 27789056

Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression.

Masahiro Nezu1, Tomokazu Souma2, Lei Yu3, Takafumi Suzuki3, Daisuke Saigusa4, Sadayoshi Ito5, Norio Suzuki6, Masayuki Yamamoto7.   

Abstract

Acute kidney injury is a devastating disease with high morbidity in hospitalized patients and contributes to the pathogenesis of chronic kidney disease. An underlying mechanism of acute kidney injury involves ischemia-reperfusion injury which, in turn, induces oxidative stress and provokes organ damage. Nrf2 is a master transcription factor that regulates the cellular response to oxidative stress. Here, we examined the role of Nrf2 in the progression of ischemia-reperfusion injury-induced kidney damage in mice using genetic and pharmacological approaches. Both global and tubular-specific Nrf2 activation enhanced gene expression of antioxidant and NADPH synthesis enzymes, including glucose-6-phosphate dehydrogenase, and ameliorated both the initiation of injury in the outer medulla and the progression of tubular damage in the cortex. Myeloid-specific Nrf2 activation was ineffective. Short-term administration of the Nrf2 inducer CDDO during the initial phase of injury ameliorated the late phase of tubular damage. This inducer effectively protected the human proximal tubular cell line HK-2 from oxidative stress-mediated cell death while glucose-6-phosphate dehydrogenase knockdown increased intracellular reactive oxygen species. These findings demonstrate that tubular hyperactivation of Nrf2 in the initial phase of injury prevents the progression of reactive oxygen species-mediated tubular damage by inducing antioxidant enzymes and NADPH synthesis. Thus, Nrf2 may be a promising therapeutic target for preventing acute kidney injury to chronic kidney disease transition.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute kidney injury; chronic kidney disease; ischemia reperfusion; oxidative stress; transcription regulation

Mesh:

Substances:

Year:  2016        PMID: 27789056     DOI: 10.1016/j.kint.2016.08.023

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  63 in total

Review 1.  Ferroptosis and kidney diseases.

Authors:  Shumei Tang; Xiangcheng Xiao
Journal:  Int Urol Nephrol       Date:  2019-11-25       Impact factor: 2.370

2.  Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice.

Authors:  Nadine Keleku-Lukwete; Mikiko Suzuki; Harit Panda; Akihito Otsuki; Fumiki Katsuoka; Ritsumi Saito; Daisuke Saigusa; Akira Uruno; Masayuki Yamamoto
Journal:  Blood Adv       Date:  2019-04-23

3.  Reducing Inflammatory Cytokine Production from Renal Collecting Duct Cells by Inhibiting GATA2 Ameliorates Acute Kidney Injury.

Authors:  Lei Yu; Takashi Moriguchi; Hiroshi Kaneko; Makiko Hayashi; Atsushi Hasegawa; Masahiro Nezu; Hideyuki Saya; Masayuki Yamamoto; Ritsuko Shimizu
Journal:  Mol Cell Biol       Date:  2017-10-27       Impact factor: 4.272

Review 4.  Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress.

Authors:  Takafumi Suzuki; Masayuki Yamamoto
Journal:  J Biol Chem       Date:  2017-08-24       Impact factor: 5.157

5.  The role of natural products in revealing NRF2 function.

Authors:  Donna D Zhang; Eli Chapman
Journal:  Nat Prod Rep       Date:  2020-05-13       Impact factor: 13.423

6.  Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability.

Authors:  Phillip R Lazzara; Brian P David; Aparna Ankireddy; Benjamin G Richardson; Katherine Dye; Kiira M Ratia; Sekhar P Reddy; Terry W Moore
Journal:  J Med Chem       Date:  2019-11-14       Impact factor: 7.446

7.  Synthesis and Evaluation of Noncovalent Naphthalene-Based KEAP1-NRF2 Inhibitors.

Authors:  Phillip R Lazzara; Atul D Jain; Amanda C Maldonado; Benjamin Richardson; Kornelia J Skowron; Brian P David; Zamia Siddiqui; Kiira M Ratia; Terry W Moore
Journal:  ACS Med Chem Lett       Date:  2020-02-19       Impact factor: 4.345

Review 8.  Nitrolipids in kidney physiology and disease.

Authors:  Soma Jobbagy; Roderick J Tan
Journal:  Nitric Oxide       Date:  2018-03-29       Impact factor: 4.427

Review 9.  Novel treatment strategies for chronic kidney disease: insights from the animal kingdom.

Authors:  Peter Stenvinkel; Johanna Painer; Makoto Kuro-O; Miguel Lanaspa; Walter Arnold; Thomas Ruf; Paul G Shiels; Richard J Johnson
Journal:  Nat Rev Nephrol       Date:  2018-01-15       Impact factor: 28.314

Review 10.  AKI: an increasingly recognized risk factor for CKD development and progression.

Authors:  J T Kurzhagen; S Dellepiane; V Cantaluppi; H Rabb
Journal:  J Nephrol       Date:  2020-07-10       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.